Profile
VeriLuce Therapeutics is an R&D/early-stage drug development company currently developing novel small molecules targeting concomitantly two chemokine receptors in dual antagonistic mode. The objective is to target such receptors within the tumour microenvironment to modulate the immune system to activate tumour-killing immune cells and suppress tumour-enhancing immune cells. Potential target indications for treatment include Triple Negative Breast cancer and Hepatocellular Carcinoma.
Event details
Date: June 3 - 6, 2024
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
Displaying 1 - 12 of 42
-
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved…
-
Altis Labs is a computational imaging company advancing precision medicine. The company believes that medical imaging…
-
CCRM is a Canadian public-private partnership established with seed funding by the Government of…
-
The City of Brampton Economic Development Office provides business connections, site selection services and access to…
-
Mississauga's life sciences sector is a thriving hub of innovation and growth. With a highly skilled workforce and…
-
Clinical Trials Ontario (CTO) is a leading organization in the clinical trials community dedicated to…
-
Covar Pharmaceuticals delivers customized services for pharmaceutical development of new or existing drugs, novel…
-
Custom Biologics provides regulatory compliant potency testing and assay services for all phases of biotherapeutic drug…
-
Esphera SynBio is a pre-clinical company developing the next generation of exosome-based therapeutics. Their…
-
For over two decades, Toronto area-based GL CHEMTEC has been dedicated to delivering innovative solutions…
-
HDAX Therapeutics is pioneering best-in-class therapeutics for neurological and cardiovascular diseases. Leveraging its…
-
ImmunoBiochem is an innovative biopharmaceutical company on a mission to develop novel bioconjugate therapeutics, such…